Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

This study has been completed.
Sponsor:
Collaborators:
Aventis Pharmaceuticals
Rhone-Poulenc Rorer
Information provided by (Responsible Party):
University of Michigan Cancer Center
ClinicalTrials.gov Identifier:
NCT00148070
First received: September 2, 2005
Last updated: October 3, 2012
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2006
  Primary Completion Date: September 2004 (Final data collection date for primary outcome measure)